within Pharmacolibrary.Drugs.ATC.J;

model J05AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.0,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fosfonet is not a recognized or approved medication in any pharmacological or clinical context. There is no such drug listed under ATC code J05AD02. The ATC code J05AD02 belongs to Foscarnet, an antiviral drug used primarily to treat cytomegalovirus (CMV) infections in immunocompromised patients, including those with HIV/AIDS or undergoing organ transplantation.</p><h4>Pharmacokinetics</h4><p>No pharmacokinetic studies or publications exist for 'fosfonet'. Estimates cannot be reliably provided for a non-existent or unapproved compound.</p><h4>References</h4><ol><li>P S Lietman,Clinical pharmacology: foscarnet.,The American journal of medicine,1992<a href='https://pubmed.ncbi.nlm.nih.gov/1371039/'>https://pubmed.ncbi.nlm.nih.gov/1371039/</a></li><li>Arianna Mareri, Stefania Lasorella, Giulia Iapadre, Maria Maresca, Renato Tambucci, Giovanni Nigro,Anti-viral therapy for congenital cytomegalovirus infection: pharmacokinetics, efficacy and side effects.,The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians,2016<a href='https://pubmed.ncbi.nlm.nih.gov/26135794/'>https://pubmed.ncbi.nlm.nih.gov/26135794/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AD02;
